Tendon Study
RCT-01: Tendon Repair
In 2017, RepliCel completed a phase 1 human clinical trial of RCT-01 in patients with a chronically injured Achilles tendon. The study’s results supported the product’s safety and provided encouraging indications of its potential efficacy in restoring patient function, pain and activity levels in addition to impacting measures of tendon blood flow and structure.
RepliCel continues to advance its cell therapy and dermal injection programs through ongoing research and development.
Peer-reviewed Papers
RCT-01 for Chronic Achilles Tendinopathy
Skin-Derived Tenocyte-like Cells for the Treatment of Patellar Tendinopathy
Treatment of Lateral Epicondylitis Using Skin-Derived Tenocyte-like Cells
Posters
RCT-01 for Chronic Achilles Tendinopathy
Autologous Cell Treatment for Achilles Tendinosis: A Phase I/II Clinical Trial
